Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial
German Center for Lung Research · LungenClinic Grosshansdorf · +19 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
933
total citations
- FWCI
- 100.78
- Percentile
- 100%
- References
- 38
Citations per year
Authors
40- MRMartin ReckCorresponding
German Center for Lung Research, LungenClinic Grosshansdorf
- TMTony Mok
Chinese University of Hong Kong
- MNMakoto Nishio
The Cancer Institute Hospital, Japanese Foundation For Cancer Research
- RMRobert M. Jotte
Texas Oncology, Rocky Mountain Cancer Centers
- FCFederico Cappuzzo
Azienda Unità Sanitaria Locale Della Romagna
Topics & keywords
Topics
Keywords
- Medicine
- Atezolizumab
- Bevacizumab
- Oncology
- Internal medicine
- Lung cancer
- Chemotherapy
- Cancer
No related works found for this paper.